Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Kumar

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|September 12, 2012
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosisM A Gertz, M Q Lacy, A Dispenzieri, et al.
Leukemia|June 29, 2020
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progressionAngela Dispenzieri, D R Larson, S V Rajkumar, et al.
Physical Review Letters|May 28, 2013
Chain conformation in polymer nanocomposites with uniformly dispersed nanoparticlesM K Crawford, R J Smalley, G Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvalsR Kurzrock, L A Gurski, R W Carlson, et al.
Bone Marrow Transplantation|September 25, 2012
Second auto-SCT for treatment of relapsed multiple myelomaW I Gonsalves, M A Gertz, M Q Lacy, et al.
Leukemia|October 12, 2011
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapyS Sinha, M Lacy, J Mikhael, et al.
Bone Marrow Transplantation|March 12, 2008
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCTS K Kumar, D Dingli, A Dispenzieri, et al.
Leukemia|March 22, 2013
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaS V Rajkumar, V Gupta, R Fonseca, et al.
Leukemia|March 8, 2019
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Leukemia|December 20, 2017
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|September 12, 2012
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosisM A Gertz, M Q Lacy, A Dispenzieri, et al.
Leukemia|June 29, 2020
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progressionAngela Dispenzieri, D R Larson, S V Rajkumar, et al.
Physical Review Letters|May 28, 2013
Chain conformation in polymer nanocomposites with uniformly dispersed nanoparticlesM K Crawford, R J Smalley, G Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvalsR Kurzrock, L A Gurski, R W Carlson, et al.
Bone Marrow Transplantation|September 25, 2012
Second auto-SCT for treatment of relapsed multiple myelomaW I Gonsalves, M A Gertz, M Q Lacy, et al.
Leukemia|October 12, 2011
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapyS Sinha, M Lacy, J Mikhael, et al.
Bone Marrow Transplantation|March 12, 2008
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCTS K Kumar, D Dingli, A Dispenzieri, et al.
Leukemia|March 22, 2013
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaS V Rajkumar, V Gupta, R Fonseca, et al.
Leukemia|March 8, 2019
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Leukemia|December 20, 2017
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Pageof 12